This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Thanks very much everyone for coming. I think, we'll get started David Friedman, Biotech Analyst. Just before we start, in terms of the disclosures, I think, everyone has been saying the same thing, personal and Morgan Stanley Holdings disclosures are available morganstanley.com/researchdisclosures, so anyway, more saving things.
We have gentlemen from AMAG Pharmaceuticals. On far side, Frank Thomas, Chief Operating Officer. In the near side, Bill Heiden, President and CEO, and we'd love this to be as interactive as possible, so anyone feel free to ask any questions at point, just raise your hand and we'll make sure we try and calling you or not just make some noise and we'll definitely find you, so thanks again for joining us.
Maybe if we can just start for those who aren't familiar or not up-to-date, if you can just give a couple-minute overview of the company, your guys' focus and where you see things headed?
Great, so I should also say that in terms of disclaimers we will be making forward-looking statements in our full disclaimers located on our website as well. I have joined AMAG about three months ago, and what I found is the company that has an asset that's best-in-class compound of product called Feraheme, which is for the treatment of IDA and chronic kidney disease, and we have the largest share of voice last couple of quarters. Very, very strong growth in terms of grams per quarter versus quarter a year ago or prior quarter, so we are seeing nice volume growth.